|Bid||0.6200 x N/A|
|Ask||0.6700 x N/A|
|Day's Range||0.5800 - 0.6700|
|52 Week Range||0.2850 - 1.3000|
|Beta (5Y Monthly)||1.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 16, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Core One Labs Inc.(CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN: A3CSSU) (the "Company" or "Core One"), in follow-up to its press release dated September 16, 2022, is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. ("Akome") has finalized study parameters and signed a contract with Fundació Bosh I Gimpera, in representation of Universitat de Barcelona (the "University of Barcelona"), to commence the second phase ("Phase 2") studies
Core One Labs Inc.(CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN: A3CSSU) (the "Company" or "Core One"), is pleased to announce that it has acquired (the "Acquisition") GMP Drug Inc. ("GMP Drug"), an arms-length privately held company that operates through a Good Manufacturing Practices ("GMP") facility (the "Facility") owned by a third-party located in Ontario, Canada.
Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce the initial production run of its psilocybin active pharmaceutical ingredient (API) product at a good manufacturing practices (GMP) facility is projected for January 2023, to test the Company's commercial production capabilities.